1 / 22

Luca Gianni Abstract 513

European Cooperative Trial in Operable Breast Cancer(ECTO): Improved freedom from progression from adding paclitaxel(T) to doxorubicin(A) followed by CMF. Luca Gianni Abstract 513. ECTO: Schema. Tumors > 2 cm randomized to : SURG ->A 75 mg/m 2 x 4 -> CMF x 4

tanner
Download Presentation

Luca Gianni Abstract 513

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. European Cooperative Trial in Operable Breast Cancer(ECTO): Improved freedom from progression from adding paclitaxel(T) to doxorubicin(A) followed by CMF Luca Gianni Abstract 513

  2. ECTO: Schema Tumors > 2 cm randomized to : SURG ->A 75 mg/m2 x 4 -> CMF x 4 SURG ->AT 60/ 200 x 4 -> CMF x 4 AT 60/ 200 x 4 -> CMF x 4 -> SURG Tam for HR + Analysis: FFP A vs B B vs C

  3. ECTO at 5 years Analysis A vs. B Pts.EventsHRp A-CMF 453 91 .66 0.01* AT-CMF 451 63 Analysis B vs. C S-AT-CMF 451 63 1.22 0.24 AT-CMF-S 451 78 Data super imposable so far, no significant difference, however pCR had improved FFP.

  4. ECTO: Main Treatment Outcomes A(%) B(%) C(%) Total FFP pCR 89 no pCR 75 N - 81 89 86 N + 1-3 79 86 71 N +>3 58 65 59 OS 82 91 90 No significant difference in OS. No significant difference in cardiac toxicity

  5. Combined Analysis ofNSABP-B31/NCCTG-N9831 Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab as Adjuvant Therapy for Patients with HER-2 Positive Operable Breast Cancer Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Swain SM, Kaufman P, Fehrenbacher L, Pisansky T, Vogel V, Kutteh LA, Yothers G, Visscher D, Brown AM, Jenkins R, Seay TE, Mamounas E, Abrams J, Wolmark N

  6. NSABP B-31 Control: ACT Arm 1 Arm 2 NCCTG N9831 Arm A Investigational: ACT+H Arm B Arm C = doxorubicin/cyclophosphamide (AC) 60/600 mg/m2 q 3 wk x 4 = paclitaxel (T) 175 mg/m2 q 3 wk x 4 = paclitaxel (T) 80 mg/m2/wk x 12 = trastuzumab (H) 4mg/kg LD + 2 mg/kg/wk x 51

  7. Patient Eligibility • HER-2 positive by FISH or +++ by IHC verified centrally (N9831) or by approved reference lab (B-31) • Normal left ventricular ejection fraction • No past or active cardiac disease including: • History of myocardial infarction • History of congestive heart failure • Angina pectoris requiring medication • Arrhythmia requiring medication • Clinically significant valvular disease • Uncontrolled hypertension • LVH • Cardiomegaly on CXR

  8. LVEF Evaluation Schedule B-31 Arm 2 / N9831 Arm C AC Paclitaxel + Trastuzumab 0 mo. 3 mos. 18 mos. 6 mos. 9 mos. B-31 Arm 1 / N9831 Arm A AC Paclitaxel 0 mo. 3 mos. 18 mos. 6 mos. 9 mos.

  9. Asymptomatic PatientsRules for Trastuzumab ContinuationBased on Serial LVEFs Within Normal Limits 1- 5 % below LLN  6 % below LLN Absolute Decrease of < 10% Absolute Decrease of 10 - 15% Absolute Decrease of  16% Relationship of LVEF to LLN Cont. Cont. Cont.* Cont. Hold * Hold * Hold * Hold * Hold * * Repeat LVEF assessment after 4 weeks - If criteria for continuation met – resume trastuzumab - If 2 consecutive holds, or total of 3 holds occur – discontinue trastuzumab

  10. B-31: Trastuzumab Discontinuation Due to Asymptomatic or Symptomatic Cardiac Dysfunction by Quarter

  11. Patient and Tumor Characteristics (%)

  12. Statistical Analysis • Median follow-up: 2.0 years (2.4 years on B-31/1.5 years on N9831) • Primary endpoint: DFS • analyzed by intent-to-treat • Secondary endpoints: OS and Time to 1st Distant Recurrence • Definitive analysis after 710 DFS events • First interim analysis after 355 DFS events • Stop trials only if equivalence is rejected at p=0.0005 (2p=0.001)

  13. Disease-Free Survival ACTH 87% 85% ACT 75% % 67% N Events ACT 1679 261 ACTH 1672 134 HR=0.48, 2P=3x10-12 B31/N9831 Years From Randomization

  14. Forest Plot For Disease-Free Survival ALL DATA Age ≥60 50-59 40-49 ≤39 Positive Negative Hormone Receptor ≥ 4.1cm 2.1- 4.0 cm <2.0 cm Tumor Size No. Positive Nodes 10+ 4-9 1-3 0 Protocol N9831 NSABP B-31 0.2 0.4 0.6 0.8 1.0 1.2 1.4 Hazard Ratio

  15. Disease-Free Survival 100 100 90 90 80 80 70 70 60 60 50 50 0 1 2 3 4 5 0 1 2 3 4 5 B-31 N9831 ACTH ACTH 87% 87% 85% ACT 86% ACT 78% 74% % 68% 66% N Events N Events ACT 807 90 ACT 872 171 ACTH 808 51 ACTH 864 83 HR=0.55, 2P=0.0005 HR=0.45, 2P=1x10-9 Years From Randomization

  16. Time to First Distant Recurrence 100 ACTH AC->T+H 90% 90% 90% 90% 90% 90% 90 ACT AC->T 80 81% 81% 81% % 74% 74% 74% 70 N Events N Events ACTH 1672 96 ACT 1679 194 AC->T 1679 194 60 AC->T+H 1672 96 HR=0.47, 2P=8x10-10 HR=0.47, 2P=8x10-10 50 0 1 2 3 4 5 Years From Randomization B31/N9831

  17. Hazard of Distant Recurrence 120 100 ACT 80 Rate per 1000 Women /Yr 60 40 ACTH 20 0 0 1 2 3 4 B31/N9831 Years From Randomization

  18. B-31/N9831 Survival ACTH 94% 91% ACT 92% 87% N Deaths ACT 1679 92 ACTH 1672 62 HR=0.67, 2P=0.015 Years From Randomization B31/N9831

  19. B-31: Post-AC LVEF and Age Are Independent Predictors of Trastuzumab-Associated CHF Age LVEF (%) P(Age)=0.04 P(LVEF)<0.0001

  20. Conclusions • For high risk HER-2 positive breast cancer, trastuzumab given concurrently with paclitaxel following AC chemotherapy, reduces the risk of a first breast cancer event at 3 years by 52%. • The relative risk reduction benefit was present and of similar magnitude in all subsets of patients analyzed. There is not, however, statistical power to establish efficacy in the node negative subset. • The addition of trastuzumab reduced the probability of distant recurrence by 53% at 3 years, and the hazard of developing distant metastases appears, thus far, to decrease over time.

  21. Conclusions 4. Results at a median follow-up of 2 years show a statistically significant survival advantage with a relative risk reduction of 33%. 5. The combination of trastuzumab and chemotherapy has a notable risk of cardiac toxicity. Careful monitoring of cardiac function is of vital importance if trastuzumab is to be used in the adjuvant setting.

More Related